For the quarter ending 2026-03-31, INTI has $1,433,363 in assets. $3,411,700 in debts. $1,290,978 in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 1,290,978 | 2,375,493 | 2,976,658 | 3,737,903 |
| Prepaid expenses and other assets | 84,975 | 71,507 | 87,428 | 92,025 |
| Total current assets | 1,375,953 | 2,447,000 | 3,064,086 | 3,829,928 |
| Operating lease right-of-use assets | 57,410 | 64,307 | 71,081 | 77,734 |
| Total assets | 1,433,363 | 2,511,307 | 3,135,167 | 3,907,662 |
| Accounts payable | 319,803 | 51,521 | 19,646 | 106,249 |
| Accrued expenses and other liabilities | 33,536 | 690,085 | 40,432 | 7,725 |
| Current portion of operating lease obligations | 28,981 | 24,724 | 27,455 | 25,987 |
| Total current liabilities | 382,320 | 766,330 | 87,533 | 139,961 |
| Deferred revenue | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 |
| Operating lease obligations, less current portion | 29,380 | 36,889 | 44,181 | 52,064 |
| Total liabilities | 3,411,700 | 3,803,219 | 3,131,714 | 3,192,025 |
| Preferred stock, value-Series APreferred Stock | - | - | 0 | 0 |
| Preferred stock, value-Series BConvertible Preferred Stock | - | - | 0 | 0 |
| Preferred stock, value-Undesignated Preferred Stock | - | - | 0 | 0 |
| Common stock, 0.0001 par value 500,000,000 shares authorized 172,573,545 shares issued and outstanding at march 31, 2026 and december 31, 2025 | 17,257 | 17,257 | 17,257 | 17,257 |
| Additional paid-in capital | 54,110,425 | 54,110,425 | 54,110,425 | 54,110,425 |
| Accumulated deficit | -56,106,019 | -55,419,594 | -54,124,229 | -53,412,045 |
| Total stockholders deficit | -1,978,337 | -1,291,912 | 3,453 | 715,637 |
| Total liabilities and stockholders deficit | 1,433,363 | 2,511,307 | 3,135,167 | 3,907,662 |
Inhibitor Therapeutics, Inc. (INTI)
Inhibitor Therapeutics, Inc. (INTI)